Clinical Trial Update: Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for an antigen-specific cancer immunotherapeutic in patients with inoperable metastatic cutaneous melanoma has completed, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GSK2132231A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-27